Innovent and UNION therapeutics reached a strategic cooperation to introduce next-generation PDE4 inhibitors for the treatment of inflammatory skin diseases

San Francisco, USA, Suzhou, China, and Hellerup, Denmark, September 28, 2021/PRNewswire/ - Cinda Biopharmaceutical Group (Hong Kong Stock Exchange stock code: 01801), a company dedicated to R&D, production and sales A biopharmaceutical company with innovative drugs for the treatment of major diseases such as tumors, metabolic diseases, and autoimmunity, and UNION therapeutics ("UNION"), a non-listed pharmaceutical company that focuses on immunology and infectious diseases and has multiple clinical stage pipelines, today The two parties jointly announced that UNION’s main drug candidate for the treatment of inflammatory skin diseases, orismilast, a potential best-in-class PDE4 inhibitor in clinical phase 2, reached an exclusive agreement in China (including Mainland China, Hong Kong, Macau and Taiwan) License agreement

According to the terms of the agreement, Cinda Bio will obtain the exclusive rights to research, development and commercialization of orismilast in China

There are approximately 50 million patients with atopic dermatitis and 6 million patients with psoriasis in China, and the incidence is showing a gradual increase with changes in life>

Dr.

Kim Kjoller, CEO of UNION therapeutics, said: "Cinda Bio is our ideal partner.

About orismilast

Orismilast is a potent and highly selective next-generation PDE4 inhibitor with a wide range of anti-inflammatory properties

About UNION therapeutics

UNION therapeutics is a non-listed pharmaceutical company specializing in immunology and infectious diseases with multiple clinical stage pipelines

"Starting from the letter, reaching the line", to develop high-quality biological drugs that the common people can afford is the ideal and goal of Cinda Bio

Since its establishment, the company has stood out among many biopharmaceutical companies with its innovative achievements and international operating model

Cinda Bio has established an internationally advanced high-end biopharmaceutical development and industrialization talent team, including many returned experts, and has cooperated with international partners such as Eli Lilly, Adimab, Incyte, MD Anderson Cancer Center and Hanmi of South Korea.

Forward-looking statement

The information published in this press release may contain certain forward-looking statements

These forward-looking statements are based on the current views, assumptions, expectations, estimates, forecasts and understandings of the company’s management on future affairs at the time the statement is made

Source: Cinda Bio